Diverse Biotech Inc, a United States-based biopharmaceutical company, has named Stella Vnook as its new chief executive officer, it was reported yesterday.
Vnook has more than 25 years' experience. She has most recently held senior leadership roles at Assertio Pharma, Jazz Pharmaceuticals, Catalent and Merck. She started her career in Research and Development in the Emergency Department at Temple University Hospital and later continued that work with oncology specialty interest at Temple/Fox Chase Cancer Centre as a pharmacist. Throughout her career she has developed extensive knowledge in many different therapy categories with a particular emphasis on Oncology, Pain Management and Cardiovascular Diseases.
William Fisher, Diverse Biotech's board chairman, said, 'Diverse Biotech is very excited to bring Stella on board as an experienced, knowledgeable, and innovative Senior Leader. Stella will work hand in hand with the current Diverse Biotech Board to continue to build a world class, innovative, experienced Executive Team.'
Camurus receives Canadian approval for Oczyesa XR for acromegaly
Akeso reports first patient dosed in Phase III study of cadonilimab in colon cancer
Glaukos reports positive Phase 4 results for iDose TR with cataract surgery
Medincell partner Teva secures FDA approval for monthly schizophrenia treatment
Alumis reports new Phase 3 data showing sustained skin clearance with envudeucitinib
FDA approves Genentech's Tecentriq combination therapy for stage III colon cancer
Sophos IRB and ALCMI partner to support lung cancer research
Innovent Biologics achieves primary study endpoint for inactive thyroid eye disease antibody
argenx reports positive Phase 2 results for FB102 in coeliac disease
Vir Biotechnology's VIR-5500 receives FDA Fast Track designation for prostate cancer
FDA accepts Bayer's application for KERENDIA in chronic kidney disease without diabetes
WuXi AppTec awarded EcoVadis gold medal for third year
Suzhou Ribo Life Science submits Phase I Clinical Trial Application for RBD3133 in EU